Evaluating Photodynamic Therapy vs. Subthreshold Micropulse Laser for Central Serous Chorioretinopathy: A Retrospective Study
Klinische Monatsblätter für Augenheilkunde · 01.04.2025 · 242 (04) · 405-412
DOI: 10.1055/a-2542-4969 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 01.04.2025. Verfasst von Tahm Spitznagel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Stadtspital Zürich Triemli, Zurich, Switzerland. Hauptthemen laut MEDLINE: Central Serous Chorioretinopathy, Photochemotherapy, Verteporfin. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Our study aims to compare the efficacy of half-dose photodynamic therapy with verteporfin (PDT) and subthreshold micropulse laser (SML) in patients with central serous chorioretinopathy (CSCR) with regards to subretinal fluid (SRF) resorption, visual acuity (VA), and central subfield thickness (CST). Patients and Methods We conducted a retrospective multicentre clinical study at the Departments of Ophthalmology at the University Hospital Zurich and Stadtspital Zürich, Switzerland. The study included patients with acute and chronic CSCR who underwent PDT, SML, or both sequentially between June 1, 2020 and December 31, 2023. The primary outcome was the reduction in SRF at three and six months post-treatment. The secondary outcomes included change in CST VA at the same intervals.
Results
A total of eighty-one eyes were analysed (33 PDT, 35 SML, thirteen combined). SRF reduction was statistically significant at both three and six months in the PDT (p < 0.001) and SML groups (p < 0.001). The combined treatment group showed a significant reduction in SRF only at six months (p = 0.001). At three months, PDT resulted in a significantly greater SRF reduction than the combined group.
Conclusions
Both PDT and SML demonstrated improvements in SRF, CST and VA, with SML presenting as a comparable alternative, particularly in cases where access to verteporfin is limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Stadtspital Zürich Triemli, Zurich, Switzerland.
- Spross Research Institute, Zurich, Switzerland.
- Department of Ophthalmology, University Hospital Zurich, Switzerland.
- Department of Ophthalmology, Hunter New England Health, New Lambton, Australia.
- Department of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institiutet, Stockholm, Sweden.
- Augenklinik, Gutblick Research, Pfäffikon, Switzerland.
ORCID-Profile: Amr Saad, Gabor Mark Somfai
Zitieren
APA
Spitznagel, T., Fasler, K., Zoellin, J., Gunzinger, J. M., Sommer, C., Kinzl, S., Muth, D. R., Turgut, F., Saad, A., Becker, M., Somfai, G. M., & Zweifel, S. (2025). Evaluating Photodynamic Therapy vs. Subthreshold Micropulse Laser for Central Serous Chorioretinopathy: A Retrospective Study. Klinische Monatsblätter für Augenheilkunde, 242(04), 405-412. https://doi.org/10.1055/a-2542-4969
Vancouver
Spitznagel T, Fasler K, Zoellin J, Gunzinger JM, Sommer C, Kinzl S, et al. Evaluating Photodynamic Therapy vs. Subthreshold Micropulse Laser for Central Serous Chorioretinopathy: A Retrospective Study. Klinische Monatsblätter für Augenheilkunde. 2025;242(04):405-412. doi:10.1055/a-2542-4969
BibTeX
@article{Spitznagel2025,
author = {Spitznagel, Tahm and Fasler, Katrin and Zoellin, Jay and Gunzinger, Jeanne Martine and Sommer, Chiara and Kinzl, Stephan and Muth, Daniel Rudolf and Turgut, Ferhat and Saad, Amr and Becker, Matthias and Somfai, Gabor Mark and Zweifel, Sandrine},
title = {Evaluating Photodynamic Therapy vs. Subthreshold Micropulse Laser for Central Serous Chorioretinopathy: A Retrospective Study},
journal = {Klinische Monatsblätter für Augenheilkunde},
year = {2025},
volume = {242},
number = {04},
pages = {405--412},
doi = {10.1055/a-2542-4969}
}
EUVIMED